Skip to main content

Month: May 2022

Proactive news headlines including Surefire Resources, KGL Resources, Race Oncology and Incannex Healthcare

Sydney, May 12, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Surefire Resources NL (ASX:SRN) is set to begin the next phase of drilling at the Yidby Road deposit within the Yidby Gold Project in Western Australia. Click here KGL Resources Ltd (ASX:KGL) has enhanced the skillset of its board through the appointment of experienced resources industry executive Jeff Gerard as an independent non-executive director. Click here Race Oncology Ltd (ASX:RAC) has received research governance office approval from the Calvary Mater Newcastle Hospital for its open label clinical trial of Zantrene® (bisantrene dihydrochloride) in patients with extramedullary acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Click...

Continue reading

MT Højgaard Holding A/S: Continued growth in challenging market

MT Højgaard Holding publishes its interim financial report for the first quarter of 2022 with the following highlights: FIRST QUARTER HIGHLIGHTS The first-quarter results met expectations. The construction industry is highly affected by price and supply problems concerning building materials, but these problems only had a minor impact on the financial results for the first quarter of the year. However, the business units’ focus on how to address the problems was substantial.Revenue increased by 25.5% to DKK 1,888 million, with organic growth accounting for approx. 6.5%. Operating profit before special items was DKK 31 million, up from DKK 14 million in the first quarter of 2021. The operating margin increased by 0.6 percentage points to 1.6%. Growth was mainly attributable to MT Højgaard Danmark and Enemærke & Petersen, whereas...

Continue reading

Three-month interim report (Q1) 2022

ALK reports Q1 revenue growth of 11% with tablet sales up 24% and earnings up 20% (unaudited) ALK delivered strong financial performance in Q1, with revenue up 11% and tablets as the primary driver of growth with sales up 24%. Sales growth and efficiencies led to a further improvement in gross margin, and operating profit (EBITDA) increased by 20%. ALK’s financial outlook for 2022 is maintained. Q1 2022 financial highlightsTotal revenue increased 11% organically in local currencies to DKK 1,155 million (1,021). Currencies had a positive effect of 2 percentage points, resulting in reported growth of 13%. Tablet sales increased by 24% to DKK 583 million (466) on broad-based growth, particularly from Japan, and tablets now account for 50% of overall revenue. Combined SCIT and SLIT-drops sales increased 2% on strong growth from International...

Continue reading

Interoil Q1 2022 interim financial report

Oslo, 12 May 2022 Highlights in the periodGross production in Q1 2022 increased 6.83% compared with the Q4 of 2021. On 24th February, Russia invaded Ukraine and with this event the oil price climbed from USD 78 per barrel at the end of December 2021 to USD 98 per barrel on February. All the projections had to be revised and recalculated. The company, as well as the rest of the players in this activity, is in constant contact with experts to make a close follow-up and to perform proper and profitable business. For Interoil the situation has resulted in an increase in revenues with the consequence effect in EBITDA mainly for Colombia. The change in market conditions has required a revision and recalculation of forecasts. The Company is monitoring developments in the new scenario to take full advantage of business opportunities and favourable...

Continue reading

Maersk Drilling releases Q1 2022 Trading Statement: Continued strong commercial and operational performance

Today, the Board of Directors of The Drilling Company of 1972 A/S (“Maersk Drilling”) has adopted the trading statement for the first quarter of 2022 (Q1 2022): Financial performance for Q1 2022 (Q4 2021 in brackets)Revenue of USD 248m (USD 320m) impacted by lower utilisation, partially offset by higher financial uptime Contracted days were 1,158 (1,376) resulting in a utilisation of 68% (78%) Average day rate of USD 214k (USD 233k) Continued strong operational performance with financial uptime of 98.8% (96.9%) Secured contracts with a total contract value of USD 357m (USD 1,111m) Revenue backlog of USD 2.1bn at 31 March 2022 (USD 1.9bn at 31 December 2021). As of 31 March 2022, the forward contract coverage for the remaining part of 2022 was 68%.Guidance 2022The full-year guidance for 2022 as published on 11 February 2022 is maintained:Profit...

Continue reading

Kitron ASA – Initiation of a share buyback

(2022-05-12) Kitron ASA initiates a share buyback Kitron ASA (“Kitron” or the “Company”) has decided to initiate a buyback of up to 55 000 of its own shares for a total maximum amount of NOK 1 000 000. The buyback program may be carried out in the period from this announcement and until 19 May 2022. The share buyback program will be carried out in accordance with the EC Commission Delegated Regulation (EU) No. 2016/1052 of 8 March 2016 regarding exemptions from market manipulation for share programs. The purpose of the buyback program is to acquire shares that can be used as part of the remuneration to the board members for the period from and including May 2022, and to and including April 2023, as resolved by the annual general meeting on 27 April 2022. The Company has engaged Norne Securities AS to carry out the...

Continue reading

Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic

REGULATED INFORMATIONMont-Saint-Guibert, Belgium, 12 May 2022, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in the development of optimized formulations of arsenic salts and their application in inflammatory conditions and other potential new indications. The objective of the discussions is to explore the benefits of a potential reverse merger or a similar transaction whereby all shareholders of Medsenic would individually contribute fifty-one percent (51%) of the total outstanding...

Continue reading

KBC Group: First-quarter result of 458 million euros

Press Release Outside trading hours – Regulated information* Brussels, 12 May 2022 (07.00 a.m. CEST)          KBC Group: First-quarter result of 458 million euros ‘Just when the pandemic-related concerns had started to ease in some countries thanks to the gradual abolishment of precautionary measures, Russia invaded Ukraine in February. The tragedy unfolding in Ukraine has caused immense human suffering and we express our heartfelt solidarity with all the victims of the conflict, both those in the region itself and the large number of refugees in various guest countries in Europe. The brutal invasion is sending shockwaves throughout the global economy. Our direct exposure to Ukraine, Belarus and Russia (a mainly commercial exposure of some 55 million euros) is quite limited, but we are keeping a very close eye on the indirect macroeconomic...

Continue reading

Parrot: 2022 First-Quarter Business

  PRESS RELEASEParis, May 12, 2022, 7am CET2022 FIRST-QUARTER BUSINESS In the first quarter of 2022, the Parrot Group recorded consolidated revenues of €14.4m, up 60% year-on-year based on its reference scope, presented with the 2021 full-year earnings. Focused exclusively on the design, development and marketing of professional civil drone solutions, combining microdrones and image analysis software, the Group is seeing the benefits of its strategy rolled out since the end of 2018, against a backdrop of increased demand for its technologies.  Revenues (€m and % of revenues) Q1 2022 Q1 2021 Change FY 2021A Parrot Drones 7.7 54% 4.8 39% +60% 20.9 38%B Of which, consumer products(2) 0 0% 1.2 9% – 6.2 11%C Pix4D 6.7 46% 5.6 45% +20% 26.2 48%D Parrot SA 0.1 1% 0.1 1% – 0.3 1%E Intragroup eliminations -0.1 -1% -0.2 -2% – -0.8 -2%F SenseFly...

Continue reading

Multitude SE publishes Q1 2022 results

Helsinki, 12 May 2022 – Multitude SE (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or the “Group”) announces unaudited results for the first three months ended 31 March 2022 (“Q1 2022”). Financial HighlightsRevenue from continuing operations increased by EUR 1.5m compared to Q1 2021 Doubling of revenue compared to Q1 2021 in SweepBank EBIT, PBT, and after-tax profit amounted to EUR 5.6m, EUR 2.5m, and EUR 2.0mKey Figures, EUR million Q1 2022 Q1 2021Revenue 53.5 52.0Profit before interests and taxes (EBIT) 5.6 6.3Profit before tax 2.5 1.5Net profit from continuing operations 2.0 0.6Net Profit (loss) 2.0 (0.3)Earnings per share, basic, continuing operations (EUR)       0.09 0.03Earnings per share, basic (EUR)       0.09 (0.01)Progressive growth in portfolio size and quality The Group continues...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.